Company News: Aleva Neurotherapeutics Appoints Dr. Philippe Dro to its Board of Directors
– Seasoned entrepreneur brings 20 years of Life Science industry experience –
Aleva Neurotherapeutics, a leading company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease, today announced the appointment of Dr. Philippe Dro to its Board of Directors.
Dr. Dro brings 20 years of entrepreneurial experience in the life science industry, including a pivotal role in executing strategic transactions at several biotech and medtech companies. Until recently, he was Chief Executive Officer and a Member of the Supervisory Board of GlycoVaxyn AG, a vaccine company that was acquired by GSK earlier this year. Prior to this, he served as Chief Executive Officer and Chairman of the Board of Endoart S.A., a medtech company developing telemetry-driven implants for cardiac disease and obesity that was sold to Allergan, Inc. From 1999 to 2003, he was Chief Financial Officer and Head of Business Development at drug discovery company Axovan AG, which was acquired by Actelion in November 2003. Prior to that, he held various position at Novartis, Skyepharma, and Antares Pharma.
Dr. Dro received a doctorate in Pharmacy (Pharm D) from the School of Pharmacy of the University of Grenoble, France, and holds a joint MBA from Ecole Superieure de Commerce de Lyon, France, and Cranfield School of Management, United Kingdom.